A dark-console reading of the BPC-157 + TB-500 'Wolverine' blend — its two repair mechanisms traced channel by channel, with the regulatory and compounding-access record carried in the open.
Wolverine Meds

Reference register / 06

BPC-157 TB-500 References

Every quantitative claim on this site maps to one of the entries below. Constituent studies, structural and review literature, recent reviews, and the FDA regulatory sources.

Back to the researchRead the access status

How to read this list

The BPC-157 TB-500 references below are the complete cited basis for this site. Entries [1]-[2] and [8] are the BPC-157 constituent and review literature; [3]-[4], [6]-[7] are the TB-500 / Thymosin Beta-4 actin and review literature; [5] and [9] are the 2025-2026 systematic and narrative reviews that bound the evidence; [10] consolidates the dosage, pharmacokinetic, and regulatory-context summary; and [11]-[16] are the FDA primary sources behind the full reference list and the access page. Every entry resolves to a DOI, PMID, or an authoritative FDA URL.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  6. Tokura Y, et al. Muscle injury-induced thymosin beta4 acts as a chemoattractant for myoblasts. J Biochem. 2011;149(1):43-48. ↗
  7. Cassimeris L, Safer D, Nachmias VT, Zigmond SH. Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes. J Cell Biol. 1992;119(5):1261-1270. ↗
  8. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  9. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  10. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. (Establishes the TB-500 = Ac-LKKTETQ heptapeptide identity and the doping-control / WADA context; cited for the constituent identity, stability/handling, and prohibited-substance framing.) ↗
  11. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. (Lists BPC-157 and TB-500 among bulk drug substances 'being considered for inclusion on the 503A Bulks List'; a scheduled discussion, not a decision.) Verified 2026-05-29. ↗
  12. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA Human Drug Compounding. (Definitions of Category 1 and Category 2; the bulks-list and nomination framework; the January 7, 2025 interim-policy change for newly nominated substances.) Verified 2026-05-29. ↗
  13. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA Human Drug Compounding. (Category 2 entry for BPC-157, effective with the September 29, 2023 update; FDA's stated safety rationale.) Verified 2026-05-29. ↗
  14. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA Human Drug Compounding. (Category 2 entry for 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500,' effective with the September 29, 2023 update; FDA's stated safety rationale.) Verified 2026-05-29. ↗
  15. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA Human Drug Compounding. (Section 503A vs 503B framework; the bulk-substance eligibility conditions — USP/NF monograph, component of an approved drug, or on the applicable FDA bulks list.) Verified 2026-05-29. ↗
  16. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA Human Drug Compounding. (The lawful compounded-medication access pathway: licensed-prescriber evaluation, including telehealth as a front-end channel, valid patient-specific prescription, dispensing by a 503A pharmacy or sourcing from a 503B outsourcing facility.) Verified 2026-05-29. ↗